As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Immunometabolism has emerged as a central hub linking infection, inflammation, cell death, and cancer. The metabolic state of cells profoundly shapes their ...